Because NPI-0052 is an irreversible inhibitor, it may similarly inhibit T-cell function via NF-κB modulation; and, our current studies are examining this question using MM patient-derived T-cells and normal resting or activated T cells. The gene discussed is NFKB1; the disease is Miyoshi myopathy.